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Glyceraldehyde- 3- phosphate dehydrogenase (GAPDH) has recently gained attention 
as an antiprotozoan and anticancer drug target. We have previously identified 
2- phenoxy- 1,4- naphthoquinone as an inhibitor of both Trypanosoma brucei and 
human GAPDH. Herein, through multiple chemical, biochemical, and biological 
studies, and through the design of analogs, we confirmed the formation of a covalent 
adduct, we clarified the inhibition mechanism, and we demonstrated antitrypanoso-
mal, antiplasmodial, and cytotoxic activities in cell cultures. The overall results lent 
support to the hypothesis that 2- phenoxy- 1,4- naphthoquinone binds the GAPDH 
catalytic cysteine covalently through a phenolate displacement mechanism. By in-
vestigating the reactivity of 2- phenoxy- 1,4- naphthoquinone and its analogs with four 
GAPDH homologs, we showed that the covalent inhibition is not preceded by the 
formation of a strong non- covalent complex. However, an up to fivefold difference 
in inactivation rates among homologs hinted at structural or electrostatic differences 
of their active sites that could be exploited to further design kinetically selective in-
hibitors. Moreover, we preliminarily showed that 2- phenoxy- 1,4- naphthoquinone 
displays selectivity for GAPDHs over two other cysteine- dependent enzymes, sup-
porting its suitability as a warhead starting fragment for the design of novel 
inhibitors.
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1 |  INTRODUCTION
Glyceraldehyde- 3- phosphate dehydrogenase (GAPDH, 
EC 1.2.1.12) is the glycolytic enzyme that reversibly cata-
lyzes the conversion of glyceraldehyde- 3- phosphate (G3P) 
to 1,3- bisphosphoglyceric acid (BPGA) in the presence of 
nicotinamide adenine dinucleotide (NAD+) and inorganic 
phosphate.[1–4] The catalytic mechanism consists of two 
steps: (i) the nucleophilic attack of the catalytic cysteine 
of the active site on the aldehyde group of G3P, followed 
by a hydride transfer to the nicotinamide ring, and (ii) the 
phosphorolysis of the thioester by inorganic phosphate 
(Figure 1a). The conformational transition at the active site 
during catalysis has been observed crystallographically.[5] 
The reactivity of the catalytic cysteine of GAPDH toward 
G3P has been ascribed to a pKa of 6.0
[6] lower than that of 
free thiols, such as glutathione (pKa = 8.6),
[7] and unreac-
tive solvent- exposed cysteine residues (pKa = 8.4).
[6,8] The 
low pKa reflects the involvement of the catalytic cysteine 
in a cysteine–histidine catalytic dyad, which provides a 
pKa- lowering microenvironment that stabilizes the thiolate 
species.[6,9] Consistently with its distinctive pKa, the cat-
alytic cysteine of GAPDHs was shown to react with sev-
eral chemically diverse electrophiles, such as iodoacetic 
acid,[1] acrylonitrile,[10] N- acetyl- p- benzoquinone imine,[11] 
vinyl sulfones,[12] 9,10- phenanthrenequinone,[13] and 
3- bromo- isoxazoline.[14,15]
GAPDH has received considerable attention as a poten-
tial drug target.[16] Particularly, GAPDHs from protozoan 
parasites have been validated as suitable molecular targets 
for antiparasitic drugs, as several pathogenic protozoa en-
tirely depend on glycolysis as the source of ATP in the host 
stage. For instance, the absence of the pyruvate dehydro-
genase complex in the mitochondria of Plasmodium falci-
parum (Pf) restricts its ATP production to glycolysis,[17] an 
observation that prompted the structure- based drug design 
of PfGAPDH inhibitors.[14,15] The unusual compartmen-
talization of glycolysis inside the specialized organelle 
glycosome in Trypanosoma and Leishmania suggested 
the development of GAPDH inhibitors for the treatment 
of Trypanosomatidae diseases.[18,19] The identification of 
several small- molecule inhibitors,[20–24] together with ge-
netic validation by RNAi experiments,[25] has confirmed its 
druggability. In parallel, human GAPDH (hGAPDH) has 
emerged as an appealing target for anticancer therapy.[26] 
Indeed, an increased expression of hGAPDH in different 
types of cancer has been associated with enhanced gly-
colytic capacity, facilitating tumor progression.[26] Tumor 
cells mostly rely on glycolysis for ATP production (Warburg 
effect), making GAPDH inhibition an ideal strategy to 
specifically hit them with minimal systemic toxicity.[26] 
Indeed, the GAPDH covalent inhibitor 3- bromopyruvate 
has recently entered the early phases of clinical trials for 
cancer treatment.[27] Besides its “classical” glycolytic role, 
F I G U R E  1  (a) Mechanism of the reaction catalyzed by GAPDH. (b) Sequence alignment of GAPDH orthologs catalytic domain used in this 
study using the BLAST algorithm. Conserved positions are highlighted in yellow, whereas catalytic residues are indicated by red boxes. [Colour 
figure can be viewed at wileyonlinelibrary.com]
(a)
(b)
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a number of recent studies have demonstrated the active 
participation of GAPDH in several non- metabolic cellular 
functions, such as apoptosis,[28] transcription activation, 
and axonal transport.[29]
In this context, our group reported the discovery and phar-
macological characterization of 2- phenoxy- naphthoquinone 
(1 in Figure 1), a promising hit compound for the treatment 
of trypanosomiases[30] and tumors.[31] We identified 1 in a 
phenotypic screening as a potent inhibitor of Trypanosoma 
brucei (Tb) growth (EC50 = 80 nm).
[30] 1 was then shown 
to act as TbGAPDH inhibitor (IC50 = 7.25 μm) by means 
of chemical proteomic approaches.[32] To further validate 
and explore the structure–activity relationships (SAR) of 
this scaffold for GAPDH inhibition, we designed and syn-
thesized a focused chemical library around 1.[31] 1 and its 
2- aryloxy- derivatives—although with flat SARs—showed 
to inhibit both TbGAPDH[31,33] and hGAPDH,[31] possibly 
through covalent binding to the catalytic cysteine. In this 
respect, we speculated that 1 and its derivatives might un-
dergo a nucleophilic substitution reaction at carbon C2 by 
TbGAPDH catalytic cysteine, leading to phenolate displace-
ment as leaving group and formation of the corresponding 
substitution adduct.[31–33] However, the exact mechanism of 
inhibition remains poorly understood at this time.
In this report, we investigated in depth the cova-
lent inhibition mechanism of GAPDH inhibition by 
2- phenoxy- naphthoquinones using multiple chemical, bio-
chemical, and biological methods on GAPDH orthologs 
(hGAPDH, TbGAPDH, PfGAPDH, Arabidopsis thaliana 
GAPDH, AtGAPDH). Several experimental evidences con-
firming a phenolate displacement mechanism were col-
lected. We also explored the enzymatic activity profile of 
purposely designed chemical probes (2–4 in Table 1) in 
comparison with 1, together with their antiparasitic and cy-
totoxic activities.
2 |  EXPERIMENTAL SECTION
2.1 | Materials
Chemicals were of the best commercial quality available and 
were purchased from Sigma- Aldrich (St. Louis, MO, USA). 
DL- Glyceraldehyde 3- phosphate (G3P) was prepared by hy-
drolysis of the G3P diethyl acetal barium salt according to 
the manufacturer’s instructions. Stocks at 34 mm concentra-
tion were stored at −20°C in small aliquots and thawed when 
needed.
2.2 | Protein expression and preparation
Recombinant GAPDH from Plasmodium falciparum 
(PfGAPDH) was prepared as previously described.[14] 
Recombinant human GAPDH (hGAPDH) was expressed 
from a pET28- derived vector containing the synthetic 
gene (NCBI protein accession NP_001276675.1) codon- 
optimized for Escherichia coli (Geneart, Life Technologies) 
and then purified with conventional IMAC chromatogra-
phy, similarly to PfGAPDH.[14] Recombinant GAPC1 from 
Arabidopsis thaliana (AtGAPDH) was expressed and puri-
fied as previously reported.[34] Recombinant Trypanosoma 
brucei GAPDH (TbGAPDH) was expressed and purified as 
described in.[32] The molecular mass and purity of all proteins 
was determined by SDS- PAGE and the concentrations de-
termined both spectrophotometrically and with the Bradford 
assay.[35] The specific activities measured with our stand-
ard assay (vide infra) were 15.2, 17, 10.6, and 23 units/mg 
T A B L E  1  Antitrypanosomal, antiplasmodial, and cytotoxic profile (expressed as IC50 (μg/ml)) of 1 and related chemical probes 2–4 and 
anti- TbGAPDH activity
X R1
T. brucei rhodesiense 
IC50 (μg/ml)a,b
P. falciparum IC50  
(μg/ml)a,b
Cytotoxicity L6 IC50 
(μg/ml)a,b
% of TbGAPDH 
inhibition at 10 μmb
1 –O– –H 0.02c 1.43 1.48c 100
2 –O– –OMe 0.68c 2.41 1.71c 33
3 –O– –NO2 0.34 2.84 4.71 37
4 –NH– –H 1.24 0.18 0.93 24
aIC50 values are the concentration of an inhibitor that causes 50% growth inhibition.
bIC50 and % of TbGAPDH inhibition values are the mean of two independent determinations that varied by less than a factor of 2. The experimental error is within ±50%.
cData taken from ref.[31]
1-4
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for hGAPDH, PfGAPDH, TbGAPDH, and AtGAPDH, 
respectively.
2.3 | Enzyme assays
GAPDH activity was monitored spectroscopically by follow-
ing either the forward (glycolytic) or reverse (gluconeogenic) 
reactions. The oxidation of G3P was monitored using a modi-
fied version of the Ferdinand assay[36] in a buffer containing 
100 mm TEA, 10 mm sodium arseniate, 5 mm EDTA, 1.5 mm 
NAD+, and 2.8 mm G3P, at pH 7.6. GAPDHs were added 
at final concentrations of 30–80 nm, and NADH formation 
was monitored at 340 nm using a Cary4000 spectrophotom-
eter (Agilent Technologies). The gluconeogenic reaction was 
measured in an assay mixture containing 50 mm Tris–HCl, 
1 mm EDTA, 5 mm MgCl2, 3 mm 3- phosphoglycerate, 5 
units/ml of S. cerevisiae 3- phosphoglycerate kinase, 2 mm 
ATP, and 0.2 mm NADH at pH 7.5. All enzyme assays were 
carried out at 25°C.
2.4 | Inhibition assays
Protein inhibition by 1 was monitored both with the glyco-
lytic and the gluconeogenic enzyme assays. For the glyco-
lytic assays, GAPDHs (2 μm) were incubated at 25°C in a 
solution containing 100 mm TEA, 5 mm EDTA, 10 mm so-
dium arseniate at pH 7.6 in the presence of 1 at the indicated 
concentrations—with at least a fivefold excess. Aliquots 
of the reaction mixtures were periodically sampled and the 
residual enzyme activity measured. Aliquots of samples in-
cubated in the absence of 1 were assayed as controls. The 
inactivation time–courses were fitted to monoexponential 
decays to obtain the apparent inactivation rates, which were 
then analyzed in a Kitz–Wilson double reciprocal plot,[37] 
obtaining a kinact/Ki ratio for each inhibitor and for each 
GAPDH homolog. For some of these experiments, it was 
not possible to sample aliquots at the exact same time in 
replicated experiments. In these cases, at least two sets of 
inhibition kinetics were collected for each experiment and 
the statistical analysis was carried out independently on the 
resulting kinetic traces. The reported SEM are therefore as-
sociated with the calculated parameters rather than the raw 
data points.
For the inhibition assays based on the glucogenetic reac-
tion, GAPDH homologs were incubated with 1 at indicated 
concentrations in solutions containing 100 mm TEA and 
5 mm EDTA at pH 7.6. At different times, aliquots were sam-
pled from the incubation mixture and assayed for enzyme ac-
tivity. All inactivation experiments were monitored relative 
to a control sample without 1, which was set to 100% activity 
at each time- point.
The reversibility of 1 inactivation was assessed by mea-
suring GAPDH activity after 60- min treatment with 1 and 
after incubation for 10 min with 5 mm DTT. Protection as-
says by the glycolytic substrate G3P were determined by 
comparing the inactivation rates in the presence of 100 μm 
of 1 using the same conditions supplemented with 5 mm 
G3P. Protection by the gluconeogenic substrate BFGA was 
determined by adding the BPGA- generating system (3 mm 
3- phosphoglycerate, 5 units/ml of 3- phosphoglycerate ki-
nase and 2 mm ATP) to the reaction mixture where 1 was 
also present.
2.5 | Reaction kinetic studies
Compounds 1–3 were dissolved in methanol (final con-
centration 3.4 × 10−5 m), put in a quartz cuvette, and 
quickly mixed with an excess of dodecanthiol (0.1–
0.7 mm). The increase in absorption at 413 nm (At) indi-
cated the formation of the substitution product. The plots 
of ln(1 − At/At=∞) as a function of time were linear and 
provided the pseudo- first- order constant for the reaction 
of 1–3 with dodecanthiol (SH), kobs. The relationship of 
kobs on [SH] consisted of the sum of two terms: kobs = k1 
[SH] + k2 (KSH)
1/2 [SH]1/2, accounting for the reaction of 
1–3 with dodecanthiol (SH) and with dodecanthiolate (S−), 
as [S−] = (KSH [SH])
1/2. The values of k2 reported in Figure 
6 were obtained from the known value of KSH in methanol. 
The results are the mean of two independent determina-
tions that varied less by 10%.
2.6 | Mass spectrometry
The alkylation of GAPDHs by 1 was assessed by incubat-
ing the proteins (20 μm) with a 10- fold excess of 1 for 1 hr. 
Protein samples were then analyzed by MALDI- TOF mass 
spectrometry using a 4800 MALDI- TOF/TOF Analyzer 
(Applied Biosystems) in linear positive mode. Briefly, 
GAPDH samples were loaded onto the MALDI plate with the 
double layer method using alpha- cyano- 4- hydroxycinnamic 
acid (CHCA) as matrix. One microlitre of 10 mg/ml CHCA 
in acetone was then deposited onto the MALDI plate and 
air- dried; a second layer was obtained by diluting 10- fold 
the sample with 20 mg/ml CHCA in 50% acetonitrile and 
0.05% TFA. Spectra of undigested GAPDH were acquired 
using the linear positive mode in the 10,000–45,000 m/z 
range.
2.7 | Parasite growth inhibition and 
cytotoxicity assays
In vitro activity against bloodstream forms of Trypanosoma 
brucei rhodesiense (STIB900), chloroquine- and 
pyrimethamine- resistant K1 Plasmodium falciparum strain, 
and cytotoxicity assessment against L6 cells were determined 
as previously reported.[38]
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3 |  RESULTS AND DISCUSSION
3.1 | Inhibition studies of GAPDH 
orthologs by 1
To evaluate a possible selectivity of 1 toward GAPDHs, 
we investigated its inhibition on four orthologs: hGAPDH, 
TbGAPDH, PfGAPDH, and AtGAPDH. Whereas the first 
three have been proposed as promising drug targets,[14,19,26] 
the molecular studies of AtGAPDH have been particularly 
pursued to unveil its moonlighting role (i.e., multifunctional 
properties involved in a large range of biological functions 
besides the glycolytic one) in higher plants.[8] The alignment 
of the amino acid sequences of the four proteins (Figure 1b) 
highlights that, with the exception of the Rossmann fold of 
the coenzyme- binding domain and the dyad residues, no clear 
identities in the catalytic domains of the four enzymes are ob-
served (Figure S1). In particular, it is difficult to localize the 
residues involved in the stabilization of the Ps and Pi sites, 
anion binding sites that have been identified in the GAPDH 
catalytic site as responsible for binding the C- 3 phosphate 
of G3P and the inorganic phosphate group, respectively.[39] 
Thus, it is conceivable that 1 might exhibit slightly different 
inhibitory properties toward the four orthologs.
The inactivation kinetics of the four enzymes were de-
termined at different concentrations of 1 and were time- and 
concentration- dependent. In Figure 2, representative inhibi-
tion time–courses for hGAPDH at different concentrations of 
1 (50–200 μm) (Panel a) and inhibition time–courses for all 
orthologs at a fixed concentration of 1 (100 μm) (Panel b) are 
reported. An analysis of the plots clearly showed that the four 
orthologs exhibited different inactivation profiles (Figure 2b). 
In particular, in the presence of 100 μm 1, PfGAPDH exhibited 
the fastest inactivation kinetic in comparison with the other 
homologs, with a t1/2 of around 10 min; AtGAPDH and 
TbGAPDH were the slowest reacting isoforms, with t1/2s 
around 80 min. hGAPDH exhibited an intermediate reactiv-
ity toward 1, with a t1/2 of around 40 min. The reactivity scale 
observed by monitoring the reversible oxidation of G3P (for-
ward reaction, Figure 3a) closely paralleled that observed by 
following the reverse reaction, that is, the reduction in BPGA 
(Figure 3b).
Inactivation by 1 was not reversed by addition of dithioth-
reitol (DTT) at 5 mm concentration (Figure S2), arguing for a 
non- oxidative modification of the cysteine as the underlying 
biochemical mechanism. Indeed, being DTT a thiol- based re-
ductant, it could be excluded that the formation of a disulfide 
bond involving the cysteine thiol occurs.[40] As reported for 
a similar experiment performed with metalloporphyrin de-
rivatives and apocytochrome c, this might be suggestive of 
a thioether bond formation between 1 and the protein (vide 
infra).[40]
To investigate whether inactivation of GAPDH by 1 oc-
curred as a result of interactions at the active site, substrate 
protection experiments were carried out. When either G3P 
or BPGA was added to the incubation mixtures containing 
1, they dramatically slowed down the inactivation kinetics of 
all isoforms (Figure 3, Panel b), suggesting a competition for 
the binding at the same residue, that is, the catalytic cysteine. 
The alternative possibility that GAPDH inactivation is asso-
ciated with a 1- mediated modification of cysteine residues 
other than the catalytic one—triggering an allosteric confor-
mational change to an inactive form—cannot be ruled out. 
However, to the best of our knowledge, no covalent inhibitor 
able to selectively modify GAPDH non- catalytic cysteines 
F I G U R E  2  Representative time–courses of GAPDHs inactivation (forward reaction) by 1 in TEA buffer at pH 7.6. (a) Exemplary comparison 
of the inhibition kinetics for one of the GAPDH orthologs, hGAPDH, at different concentrations of 1: 50 μm (closed circles), 100 μm (open circles), 
and 200 μm (closed triangles). (b) Exemplary comparison of inhibition kinetics at one concentration of 1 (100 μm) for hGAPDH (open squares), 
PfGAPDH (closed circles), AtGAPDH (closed triangles), and TbGAPDH (open circles). The activities were normalized to those measured in the 
absence of inhibitors for each ortholog. The lines are the fittings of the experimental points to an exponential decay. Both incubation and enzyme 
assays were carried out at 25°C. The overall analysis of these measurements and their replicates is reported in Figure 4
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(and not the catalytic one) has been reported. Therefore, the 
monoalkylation observed in mass spectrometry (vide infra) 
further suggests that the alkylated cysteine is indeed the cat-
alytic one.
3.2 | Dialysis studies on hGAPDH- 1 complex
To determine whether the observed time- dependent inhibi-
tion is irreversible, we performed dialysis studies. In the case 
of irreversible inhibition, the dialysis of the enzyme–inhibitor 
mixture should fail to free the enzyme from the inhibitor and 
to restore the enzymatic activity. Indeed, the irreversibility of 
the binding of 1 was demonstrated by incubating hGAPDH 
with 200 μm 1 in TEA buffer, pH 7.6, for 2 hr at 20°C, until 
full inhibition was achieved. Extensive dialysis against 1- free 
TEA- buffered solutions for 5 hr at 4°C did not bring about 
any recovery in activity. Control enzyme solutions subjected 
to all steps in the absence of 1 showed minimal loss in activ-
ity (Figure S3), indicating that the proteins do not undergo 
significant non- specific inactivation during the procedure. 
These data are consistent with evidence from previous dilu-
tion studies[32] and, overall, support an irreversible inhibition.
3.3 | Kitz–Wilson analysis of inhibition  
kinetics
The inhibition time–courses were analyzed as Kitz–Wilson 
double reciprocal plots (Figure 4), which describe the de-
pendence of the reaction rates on the concentration of inhibi-
tor for irreversible inactivation.[37] The reaction parameters 
were determined by fitting the dependencies to Equation 1.
The y- intercept affords the kinact, the maximum rate of 
inactivation at saturating concentration, whereas the slope 
gives the kinact/Ki ratio, the apparent second- rate constant of 
inactivation. Higher kinact/Ki values indicate higher inhibi-
tory potency. The calculated kinact/Ki ratios (see the table of 
Figure 4) confirmed that 1 reacted fivefold more efficiently 
(1)kobs=
kinact[I]
K
i
+ [I]
F I G U R E  3  (a) Protection of GAPDHs toward 1 inactivation (forward reaction) by the substrate G3P. PfGAPDH was incubated in TEA buffer 
at pH 7.6 in the presence of 100 μm of 1 (closed squares) or 100 μm of 1 + 5 mm G3P (open circles). Both incubation and enzyme assays were 
carried out at 25°C. The solid lines represent a fitting of the experimental points to exponential decays. (b) Inhibition of 1 (100 μm) on the reduction 
in BPGA (reverse reaction) by GAPDH orthologs in the presence of NADH. Residual reactivities were monitored after 15 min of incubation with 
1 in TEA buffer at pH 7.6 (black bars). The presence of a BPGA- generating system (3 mm 3- phosphoglycerate, 5 units/ml of 3- phosphoglycerate 
kinase, and 2 mm ATP) during incubation with 1 protected the enzyme from inactivation almost completely within 15 min (white bars). Both 
incubation and enzyme assays were carried out at 25°C. The error bars represent the standard deviation of three replicates
F I G U R E  4  Kitz–Wilson double reciprocal plots of the inhibition 
of PfGAPDH (open squares), hGAPDH (closed triangles), AtGAPDH 
(closed squares), and TbGAPDH (open circles) by 1 in the 50–300 μm 
concentration range. Incubation was carried out in TEA buffer, pH 7.6. 
Both incubation and enzyme assays were carried out at 25°C. The solid 
lines represent a linear fitting to the experimental points. The error bars 
represent the standard error of at least two replicates
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with PfGAPDH (7.8 ± 1.7 m−1 s−1) than with the Arabidopsis 
(1.8 ± 0.2 m−1 s−1) and Trypanosoma (1.5 ± 0.4 m−1 s−1) or-
thologs and twice as efficiently as with the human protein 
(3.2 ± 0.3 m−1 s−1). The poor data on TbGAPDH reflected its 
tendency to precipitate over time. The zero intercepts indi-
cated that the formation of a non- covalent complex did not 
significantly contribute to inhibition before the covalent mod-
ification, making the formation of the covalent bond the only 
mechanism of inhibition.[37] The selectivity of irreversible 
inhibitors depends both on the non- covalent binding to the 
target (Ki) and the rate at which it reacts with the target after it 
is bound (kinact), with examples of inhibitors achieving selec-
tivity exploiting either one of the two drivers or both.[41] The 
optimization of the kinact for lead compounds is usually diffi-
cult when the target nucleophile, as in the case of the catalytic 
cysteine of GAPDHs, is conserved across homologs, limiting 
the possibility to discriminate, for instance, between the pro-
tozoal isoforms and the host (human) isoform. However, here 
we showed that, despite a negligible contribution of the non- 
covalent complex in the inhibition mechanisms, 1 could be 
the starting point for the design of inhibitors that are selective 
from a kinetic point of view, that is, based on the different 
rate of the covalent bond formation.
3.4 | Reaction kinetic studies on model thiol
The biochemical data lent enough experimental support to 
the initial idea that 1 acts as an electrophilic warhead, react-
ing irreversibly with the GAPDH catalytic cysteine to form 
a covalent bond. In principle, it can occur via two possible 
chemical mechanisms:[32] (i) a 1,4- Michael addition and sub-
sequent oxidation of the intermediate hydroquinone, with 
formation of the corresponding thioether- substituted quinone 
and (ii) a substitution reaction with phenolate displacement 
(Figure 5). Both the sulfur addition and substitution reaction 
to quinones have been thoroughly explored. For instance, 
natural 2- methyl- 1,4- naphthoquinone (menadione) was 
found to covalently bind to the cysteine residue of human 
oxyhemoglobin via the 1,4- Michael- type of thiol addition 
to quinones.[42] However, the fact that the displacement of 
leaving groups by sulfur nucleophiles is a common method 
for the synthesis of thioethers,[43] together with the pres-
ence of a good leaving group (phenoxy) in position 2 of 1, 
pointed to the substitution reaction as the more plausible one. 
In fact, in the case of quinones carrying a substituent acting 
as a leaving group and with a minimal steric hindrance, it 
has been reported that the position of attack of a sulfur nu-
cleophile occurs at the site of the quinone substituent, giving 
rise to an ipso substitution product.[43,44] Thus, the presence 
of the 2- phenoxy leaving group should make 1 more prone 
to substitution reaction, rather than S- arylation, which are 
widely described for unsubstituted 1,2- naphthoquinone[45] 
and 1,4- benzoquinone.[13] Under this hypothesis, the reactiv-
ity of 1 against a model thiol was investigated by reaction 
kinetic studies. The rate constant for the reaction between 1 
and (odorless) dodecanthiol in methanol was measured by 
following the formation of the thioether 2- dodecylthio- 1,4
- naphthoquinone (5 in Figure 6) by UV–vis spectroscopy. 
When 1 was mixed with an excess of dodecanthiol (~15 eq), 
the typical absorption band of 5 at 413 nm increased during 
the reaction following a first- order kinetic rate (see Figure 6). 
As the ipso substitution product is itself a quinone, we did 
not observe the formation of the hydroquinone A, neither the 
oxidized Michael adduct B, both resulting from reaction I 
(Figure 5). In fact, when monitoring the reaction by ESI- MS, 
only two major ions were detected corresponding to 1 and the 
substitution product 5 (see Figure S4).
At the end of the reaction, the recorded spectrum was su-
perimposable to that of an authentic sample of 5, purposely 
synthesized (see the Chemistry section in the Supporting 
Information) to clarify the formation of such adduct. In par-
ticular, the rate constants were found to depend on the square 
root of the concentration of dodecanthiol. A reaction order 
of 0.5 could be explained considering that the nucleophilic 
F I G U R E  5  Possible mechanisms by which 1 can act as an electrophilic warhead and react irreversibly with thiolates to form a covalent bond
232 |   BRUNO et al.
specie is the thiolate, which is formed in a pre- equilibrium 
step, as shown in the scheme of Figure 6. This hypothesis is 
in agreement with the fact that in MeCN, which is a poorer 
ionizing solvent than MeOH, the reaction does not occur 
(data not shown). This is also consistent with the notion that 
cysteine in GAPDH is present in a pKa- lowering microen-
vironment[8,46] and, at physiological pH, the corresponding 
thiol group exists in the highly reactive nucleophilic thiolate 
state.[6]
Along the lines of reasoning of a substitution mecha-
nism, we envisaged that the reaction kinetics of different 
2- phenoxy- 1,4- naphthoquinones with dodecanthiol should 
be influenced by the nature of the leaving group in position 2. 
Accordingly, we tested the reactivity of derivatives 2[31] and 
3 carrying a 4- methoxyphenoxy or a 4- nitrophenoxy substit-
uent, respectively. As expected, the rate constant (3 > 1 > 2) 
increases in the case of 3 carrying an electron- withdrawing 
substituent (better leaving group), with respect to the unsub-
stituted 1, and to 2, carrying an electron- donating substituent 
(worse leaving group). Notably, in the case of 3, the magni-
tude of k1 might suggest a potential reactivity also toward 
undissociated thiols.
3.5 | Mass spectrometry studies of 
PfGAPDH- 1 complex
We previously failed to detect alkylation of TbGAPDH 
by mass spectroscopy,[32] mainly because of its instability. 
Therefore, MALDI- TOF analysis of undigested PfGAPDH 
was performed. The measured molecular mass of 
39,950 ± 10 Da was consistent with the loss of the ini-
tial methionine (expected molecular monoisotopic mass: 
40,081.21 Da).[14] Upon incubation of 200 μm of 1, a mass 
shift of around 145 ± 15 Da was observed, suggesting that a 
single fragment of 1,4- napthquinone (157 Da) was attached 
(Figure 7). The shift was consistent with a monoalkylation 
of each subunit, ruling out non- selective reactivity with 
other solvent- exposed cysteine residues. This observation 
suggested that 1 can react with the catalytic thiolate nucleo-
philic group of the GAPDH cysteine through mechanism II 
(vide supra). As a matter of fact, mechanism I would have 
resulted in a larger m/z shift (+250 Da for I versus +157 Da 
for II). We also failed to detect any m/z shift upon tryptic 
digestion of any GAPDH upon incubation, possibly because 
of the limited stability of the adduct in the condition used for 
MALDI spectrometry. This experiment would have allowed 
to conclusively identifying the catalytic cysteine as the reac-
tive residue.
3.6 | 1- derived chemical probes
To further probe how the presence/absence of a good leav-
ing group could affect the enzymatic activity and molecular 
mechanism of action, a properly designed analog (4) was 
synthesized. In particular, in position 2, the phenol of 1 was 
replaced by an aniline moiety. Importantly, as the aniline 
F I G U R E  6  Measure of the rate constants for the reaction between substituted phenoxy- naphthoquinones 1–3 and a model thiol in MeOH at 
25°C, studied by UV–vis spectrometry. (a) Evolution of the UV–vis spectrum of 1 and C12H25SH (both 2.4 × 10−4 m) recorded every 180 s. The 
inset shows the absorption at 413 nm as a function of time after mixing 1 (3.4 × 10−5 m) with an excess of thiol (5.0 × 10−4 m).[50] (b) Observed 
rate constants for the reaction between 1–3 and C12H25SH as a function of thiol concentration. The solid lines represent a fitting to the experimental 
points based on the scheme. (c) KSH = 4.0 × 10
−15 m. (d) Rate constants for the reaction of protonated (k1) and deprotonated (k2) thiol with 1–3, 
obtained from the fittings. The results are the mean of two independent determinations that varied less by 10%
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moiety does not act as a leaving group, it should negatively 
affect the reactivity of 4 against cysteine nucleophiles. In ad-
dition, as a non- reactive analog, 4 might provide clues into 
the initial non- covalent interaction of 1. This is because 4 
is the corresponding isoster of 1, sharing, in principle, most 
of the binding interactions with the enzyme. As expected, 
4 did not produce significant inhibition on GAPDHs. 
Considering that 4 behaves as a non- reactive analog of 1, 
we investigated the possibility that it might act as a non- 
covalent inhibitor at high concentrations. However, even at 
200 μm concentration in the assay mixture, it did not bring 
about a meaningful inhibition for PfGAPDH, the most reac-
tive of the orthologs (Figure S5), suggesting that the con-
tribution for inhibition of a non- covalent binding before the 
covalent reaction takes place is small (also supported by the 
Kitz–Wilson analysis). In addition, 4 did not display any in-
hibitory activity against AtGAPDH up to a concentration of 
50 μm, which was instead inhibited by 40% by 1 at 10 μm. 
A similar behavior was observed for hGAPDH (24% for 4 
versus 100% for 1) and TbGAPDH (20% for 4 versus 100% 
for 1) at 10 μm.
With regard to 2 (Figure 6) and analogs[31] carrying dif-
ferent leaving groups in position 2, we previously proposed 
that their inhibitory activities were correlated with both the 
possibility of properly interacting with the catalytic cyste-
ine and with their susceptibility to the subsequent nucleop-
hilic substitution reaction.[31] In this respect, docking studies 
demonstrated that steric hindrance is a major determinant 
affecting the correct positioning within the GAPDH active 
site.[31] Indeed, 3, (Figure 6), bearing the 4- nitro- phenoxy 
substituent, displayed only 37% of inhibition against 
TbGAPDH (versus 100% for 1) at 10 μm. Thus, this lower 
inhibitory activity does not seem correlated with the pres-
ence of a better leaving group, rather to the fact that the bulky 
nitro group of 3 creates steric hindrance. Conversely, 3 was 
the most effective in the reaction kinetic studies, where steric 
concern is not present.
3.7 | Whole- cell studies
We performed experiments to evaluate 2–4 in a cellular con-
text (Tb and Pf parasites, and L6 cells) in comparison with 1 
(Table 1). In the case of T. brucei, the rank in antitrypano-
somal activity perfectly matched that of GAPDH inhibition 
(1 > 3 > 2 > 4). This is not the case for the antiplasmodial 
activity, though. In fact, 4, which did not show any signifi-
cant PfGAPDH inhibitory activity, turned out to be a sub-
micromolar inhibitor of the parasite growth, suggesting an 
alternative mechanism of action, in addition to GAPDH in-
hibition. Indeed, we demonstrated that 1, thanks to its qui-
none structure, was also able to generate oxygen radicals, a 
mechanism that additionally contributes to its antiparasitic 
activity.[32]
3.8 | Activity of 1 toward cysteine proteases
1–3 all share the highly reactive 2- phenoxynaphthoquinone 
scaffold, which, in principle, is prone to unspecific covalent 
reactions with other protein thiols. Given the increased at-
tention paid to the so- called PAINS (pan- assay interference 
compounds),[47] a further discussion of 1 in relationship to 
covalent modifiers as PAINS compounds is warranted. The 
ability of the 2- phenoxyquinone moiety to act as a warhead 
can cause 1 and analogs to act as frequent hitters in screening 
assays due to interference, rather than via specific interac-
tions with the intended biological targets. In particular, the 
possibility that the inhibition is more affected by the chemical 
reactivity of the naphthoquinone moiety rather than a spe-
cific molecular recognition should be definitively ruled out. 
This concern is quite important considering that the intrin-
sic chemical reactivity of naphthoquinones 1–3 could be a 
potential limitation to their applicability in a biological con-
text, where other thiol species are expected to occur at high 
concentrations (e.g., glutathione). This is not only a concern 
for drug discovery, but also for chemical biology. Indeed, 
to this end, we preliminarily tested the inhibitory activity of 
1 against two cysteine proteases sharing with GAPDH the 
histidine–cysteine catalytic dyad, that is, human caspase- 3 
and cathepsin B. In particular, whereas caspase- 3 shows a 
pKa of 6.6,
[48] cathepsin B has a very nucleophilic active- 
site cysteine (pKa = 3.4)
[49] that can more readily react with 
thiol- modifying reagents. Notably, when tested at a concen-
tration of 10 μm, which approximates the IC50 of 1 toward 
F I G U R E  7  Mass spectra of the single charged peak of 
undigested PfGAPDH (black line) and upon incubation for 2 hr with 
1 at 200 μm concentration (gray line). A difference of 145 ± 15 Da is 
consistent with a monoalkylation by 1. The sample was diluted 1:10 
with HCCA 20 mg/ml in 75% acetonitrile and 2.5% TFA. The y- axis is 
the percent relative intensity of the signal
234 |   BRUNO et al.
TbGAPDH (IC50 = 7.25 μm),
[32] against human cathepsin B 
and caspase- 3, we could not detect any significant inhibition 
(see Supporting Information). Thus, it appears that the selec-
tive reaction of 1 with the catalytic cysteine of GAPDH is 
not because the enzyme provides an exceptionally good nu-
cleophile, and is not solely due its ability to act as an optimal 
leaving group.
4 |  CONCLUSIONS
GAPDHs are inhibited by 2- phenoxy- 1,4- naphthoquinone 
compounds through the irreversible monoalkylation of each 
subunit with a phenolate displacement mechanism. The inhi-
bition kinetics indicated that the formation of non- covalent 
complexes does not contribute significantly to inhibition, 
which appears solely associated with the formation of cova-
lent bond. However, GAPDH homologs exhibited markedly 
different reaction rates, suggesting that the microenviron-
ment of the catalytic cysteine significantly affects their re-
activity. Two cysteine proteases tested as control were not 
inhibited by 2- phenoxy- 1,4- naphthoquinone, suggesting its 
potential selectivity toward GAPDH within the cysteine- 
dependent enzymes. 2- Phenoxy- 1,4- naphthoquinone and its 
analogs showed in vivo antitrypanosomal and antiplasmodial 
activities at submicromolar concentrations. Overall, despite 
the moderate potency, the 2- phenoxy- 1,4- naphthoquinone 
scaffold can be regarded as “warhead” starting fragment for 
the identification of further inhibitors with increased po-
tency and selectivity. By fine- tuning the inherent chemical 
reactivity and exploiting the kinetic reactivities of different 
isoforms, it should be possible to tailor them to a variety 
of GAPDH isoforms that are promising therapeutic targets, 
particularly selecting analogs that are significantly more 
reactive toward parasitic orthologs in comparison with the 
human form.
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